Inimex nets $22m to advance innate defense.(Tuesday, June 3)

Inimex Pharmaceuticals Inc. is one step closer to conducting clinical trials of its innate defense regulator drugs, thanks to a successful Series B financing. The Vancouver, British Columbia-based company raised $22 million to advance its portfolio, which includes a number of potential products aimed at combating antibiotic resistance and inflammation. Inimex is developing a series of …